Literature DB >> 23428573

Late effects of radial artery vs saphenous vein grafting for multivessel coronary bypass surgery in diabetics: a propensity-matched analysis.

Thomas A Schwann1, Laila Al-Shaar, Milo Engoren, Robert H Habib.   

Abstract

OBJECTIVES: To determine whether the use of the radial artery (RA) vs the saphenous vein (SV) as the second grafting conduit with the internal thoracic artery (ITA) confers a late-survival advantage in diabetes mellitus (DM).
METHODS: We reviewed our 1996-2007 DM coronary artery bypass grafting (CABG) experience. Study patients (N = 2281) included all primary, non-salvage multigraft CABG discharged alive and receiving ≥1 ITA graft. Bilateral ITA, ITA-only grafts or concomitant valve/aortic surgery patients were excluded. A non-parsimonious, RA use propensity model (42 variables) was derived excluding five factors [gender, vessel disease, insulin, renal failure and left ventricular (LV) dysfunction] that were always strictly matched for all pairs. Greedy matching resulted in well-matched ITA/RA and ITA/SV cohorts (N = 578 each). The late follow-up was truncated at 16 years, and survival comparisons were done by Kaplan-Meier analysis.
RESULTS: RA grafting was used in 933 (41%) DM patients and was more frequent for non-insulin (513/1348; 49.1%) compared with insulin (271/784; 34.6%) dependent patients. Relatively fewer insulin ITA/RA (169; 62%) could be matched vs non-insulin (469; 71%). Late survival was significantly better for ITA/RA overall [hazard ratio, HR (95% confidence interval) = 0.78 (0.65-0.95); P = 0.012], but this was primarily due to the non-insulin sub-cohort [HR = 0.72 (0.56-0.91); P = 0.007] as opposed to no effect for insulin [HR = 0.92 (0.68-1.26); P = 0.61]. Sub-cohort analysis revealed a significant ITA/RA survival advantage in males, preserved LV function and three-vessel disease. No sub-cohorts were associated with superior ITA/SV survival.
CONCLUSION: Our analysis indicated that RA grafting confers a significant late-survival advantage and, thus, supports its liberal use in DM patients undergoing multivessel CABG.

Entities:  

Keywords:  Arterial grafting; Cardiac surgery; Diabetes mellitus; Kaplan–Meier survival analysis; Outcomes

Mesh:

Year:  2013        PMID: 23428573     DOI: 10.1093/ejcts/ezt061

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Long-term Outcomes of Multiple Arterial Coronary Artery Bypass Grafting: A Population-Based Study of Patients in British Columbia, Canada.

Authors:  Aihua Pu; Lillian Ding; Jungwon Shin; Joel Price; Peter Skarsgard; Daniel R Wong; John Bozinovski; Guy Fradet; James G Abel
Journal:  JAMA Cardiol       Date:  2017-11-01       Impact factor: 14.676

2.  Short- and long-term results of radial artery and saphenous vein grafts in the right coronary system: a propensity-matched study.

Authors:  Shohei Yoshida; Satoshi Numata; Yasushi Tsutsumi; Osamu Monta; Sachiko Yamazaki; Hiroyuki Seo; Takaaki Samura; Hirokazu Ohashi
Journal:  Surg Today       Date:  2016-08-09       Impact factor: 2.549

3.  CABG Versus PCI: Greater Benefit in Long-Term Outcomes With Multiple Arterial Bypass Grafting.

Authors:  Robert H Habib; Kamellia R Dimitrova; Sanaa A Badour; Maroun B Yammine; Abdul-Karim M El-Hage-Sleiman; Darryl M Hoffman; Charles M Geller; Thomas A Schwann; Robert F Tranbaugh
Journal:  J Am Coll Cardiol       Date:  2015-09-29       Impact factor: 24.094

4.  A meta-analysis of randomized controlled trials on mid-term angiographic outcomes for radial artery versus saphenous vein in coronary artery bypass graft surgery.

Authors:  Christopher Cao; Su C Ang; Kevin Wolak; Sheen Peeceeyen; Paul Bannon; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2013-07

5.  Coronary artery bypass grafting in young patients--insights into a distinct entity.

Authors:  Felix Fleissner; Gregor Warnecke; Serghei Cebotari; Saad Rustum; Axel Haverich; Issam Ismail
Journal:  J Cardiothorac Surg       Date:  2015-05-01       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.